Previous 10 | Next 10 |
5 Penny Stocks To Watch This Week When it comes to penny stocks , the right mix of risk and reward needs to be taken into consideration. All too often, novice traders and investors treat these cheap stocks like lottery tickets. In actuality, they are investments like any other. One of the big...
Thinly traded nano cap Stealth BioTherapeutics (NASDAQ: MITO ) is up 34% premarket on increased volume in reaction to positive results from a retrospective natural history study assessing the efficacy of subcutaneous injections of elamipretide relative to a natural history cont...
BOSTON , Feb. 18, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from it...
BOSTON , Jan. 21, 2020 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the initiation of a...
Gainers: CLPS (NASDAQ: CLPS ) +68% . More news on: CLPS Incorporation, Microbot Medical Inc., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...
Intra-Cellular Therapies (NASDAQ: ITCI ) +89% after Caplyta approved by FDA. More news on: Intra-Cellular Therapies, Inc., Cincinnati Bell Inc., Seadrill Limited, Stocks on the move, Read more ...
Gainers: Marinus Pharmaceuticals (NASDAQ: MRNS ) +42% . More news on: Marinus Pharmaceuticals, Inc., Prothena Corporation plc, Applied Genetic Technologies Corporation, Stocks on the move, Read more ...
Stealth BioTherapeutics (NASDAQ: MITO ) -56% after elamipretide flunks late-stage PMM study. More news on: Stealth BioTherapeutics Corp, Valeritas Holdings, Inc., Abeona Therapeutics Inc., Stocks on the move, Read more ...
Stealth BioTherapeutics (NASDAQ: MITO ) is poised for a significant down move after announcing unsuccessful results from a Phase 3 clinical trial, MMPOWER-3 , evaluating elamipretide in patients with primary mitochondrial myopathy (PMM), a group of inherited disorders due to mutations i...
BOSTON , Dec. 20, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced top-line dat...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...